Key Insider and Spouse Disclose 6.33% Stake in Gyre Therapeutics Post-Merger
GYRE sits 21% above its 52-week low of $6.57.
Summary
Songjiang Ma and his spouse, Yueying Zhu, have disclosed a combined 6.33% beneficial ownership in Gyre Therapeutics, including exercisable options, following the company's acquisition of Cullgen Inc.
Key Events · Ownership and Investor Activity · GYRE
-
Beneficial Ownership Update
Songjiang Ma and Yueying Zhu now beneficially own 7,342,131 shares, representing 6.33% of Gyre Therapeutics' common stock.
-
Post-Merger Disclosure
This amendment updates their ownership following the May 4, 2026, completion of the $300 million all-stock acquisition of Cullgen Inc.
-
Insider Stake
The reported ownership includes 4,536,047 shares underlying options exercisable by Mr. Ma within 60 days, indicating a significant potential stake by a key insider.
Analysis · GYRE · Life Sciences
This Schedule 13D/A updates the beneficial ownership of Songjiang Ma and Yueying Zhu, revealing their combined 6.33% stake in Gyre Therapeutics. This disclosure follows the company's recent $300 million all-stock acquisition of Cullgen Inc. While Ma and Zhu did not receive new shares in the merger, the increase in outstanding shares necessitated this update to their percentage ownership. The stake, valued at approximately $58.5 million, includes 4.5 million shares underlying options exercisable by Mr. Ma, indicating a significant long-term interest by a key insider. This filing provides further clarity on the post-merger ownership structure, complementing other recent 13D/A filings that detailed new controlling shareholders and significant stakes by Cullgen figures.
At the time of this filing, GYRE was trading at $7.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $779.8M. The 52-week trading range was $6.57 to $11.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.